Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Long-Term Deferred Tax (2022 - 2024)

Theravance Biopharma (TBPH) has disclosed Long-Term Deferred Tax for 5 consecutive years, with $2.4 million as the latest value for Q4 2024.

  • Quarterly Long-Term Deferred Tax fell 99.46% to $2.4 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2024, down 99.46% year-over-year, with the annual reading at $2.4 million for FY2024, 99.46% down from the prior year.
  • Long-Term Deferred Tax for Q4 2024 was $2.4 million at Theravance Biopharma, down from $447.3 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $447.3 million in Q4 2023, with the low at $2.4 million in Q4 2024.
  • Average Long-Term Deferred Tax over 3 years is $296.8 million, with a median of $440.7 million recorded in 2022.
  • The sharpest move saw Long-Term Deferred Tax rose 1.49% in 2023, then tumbled 99.46% in 2024.
  • Over 3 years, Long-Term Deferred Tax stood at $440.7 million in 2022, then rose by 1.49% to $447.3 million in 2023, then crashed by 99.46% to $2.4 million in 2024.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $2.4 million, $447.3 million, and $440.7 million for Q4 2024, Q4 2023, and Q4 2022 respectively.